Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 4/20 | 0.48 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.46 |
| ▸ | FNTA | P49354 | 4/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromohydrin Pyrophosphate SCHEMBL4309089 | 1.00 | MVD (0.48) | MVDBTN3A1FNTAGGPS1PGGT1B | |
| Bromohydrin Pyrophosphate SCHEMBL2037203 | 1.00 | MVD (0.48) | MVDBTN3A1FNTAGGPS1PGGT1B | |
| Bromohydrin Triphosphate SCHEMBL2034171 | 0.97 | MVD (0.46) | MVDBTN3A1FNTAGGPS1PGGT1B | |
| SCHEMBL3228433 | 0.93 | MVD (0.40) | MVDBTN3A1 | |
| SCHEMBL3003035 | 0.91 | MVD (0.39) | MVDBTN3A1 | |
| SCHEMBL3003036 | 0.91 | MVD (0.40) | MVDBTN3A1 | |
| SCHEMBL3215427 | 0.89 | MVD (0.38) | MVDBTN3A1 | |
| SCHEMBL13101843 | 0.88 | MVD (0.37) | MVDBTN3A1 | |
| SCHEMBL3228438 | 0.86 | MVD (0.35) | MVDBTN3A1 | |
| SCHEMBL21068019 | 0.85 | LPAR3 (0.39) | MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1863572-A2 | NEW CLASS OF T CELLS ACTIVATORS AND USE THEREOF | Innate Pharma (FR) | 2007-12-12 | — | — | EP | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006103568-A2 | NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF | INNATE PHARMA (FR) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006067635-A2 | USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT | INNATE PHARMA S.A. (FR) | 2006-06-29 | — | — | WO | disclosed |
| EP-1569656-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | Innate Pharma (FR) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050096-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | MVD 2944/4885BTN3A1 513/4885FNTA 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.